Modern cancer treatment by active immunotherapy
Versicherungsmedizin 66(1): 48-49
2014
ISSN/ISBN: 0933-4548 PMID: 24683906 Document Number: 673570
Document emailed within 1 workday
Related Documents
Neagoe, G.; Stoian, M. 1986: Methods of active immunotherapy and viral oncolysis in some forms of cancer Medecine Interne 24(2): 125-142Hanna, M.G.; Peters, L.C.; Hoover, H.C. 1989: Fundamentals of active specific immunotherapy of cancer using BCG-tumor cell vaccines Progress in Clinical and Biological Research 310: 51-65
Castello, G.; D'Alessio, V. 1991: Active specific immunotherapy of cancer using anti-idiotypic monoclonal antibodies La Clinica Terapeutica 137(3): 155-167
Ndiaye, M.; Dhivert-Donnadieu, H.; Demoly, P. 2003: Specific immunotherapy for respiratory allergies. a modern treatment Presse Medicale 32(32): 1508-1516
Grinevich, I.A. 1991: Nonspecific active immunotherapy in the combined treatment of malignant neoplasms Vrachebnoe Delo 5: 8-11
Mathé, G.; Hayat, M.; Amiel, J.L.; Schwarzenberg, L.; Schneider, M.; Pouillart, P.; Cattan, A. 1971: Active immunotherapy in the treatment of experimental leukemias and acute lymphoblastic leukemia in man Bollettino dell'Istituto Sieroterapico Milanese 50(4): 251-259
Mathé, G.; Halle-Pannenko, O.; Bourut, C. 1973: BCG in cancer immunotherapy: results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy National Cancer Institute Monograph 39(8): 107-113
Morton, D.L. 2004: Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma Developments in Biologicals 116: 209
Mathé, G.; Pouillart, P.; Schwarzenberg, L. 1973: Trials of active immunotherapy in the treatment of acute lymphoid leukemia: influence of diverse factors on the results Annales de Medecine Interne 124(5): 443-448
Rizvi, N.A. 2017: The use of immunotherapy in the first-line treatment of lung cancer Clinical Advances in Hematology and Oncology: H&o 15(3): 190-192
Li, P.S. 1993: The future application of adoptive immunotherapy in treatment of lung cancer Zhonghua Nei Ke Za Zhi 32(9): 579-580
Manzotti, G.; Riario-Sforza, G.G.; Dimatteo, M.; Scolari, C.; Makri, E.; Incorvaia, C. 2016: Comparing the compliance to a short schedule of subcutaneous immunotherapy and to sublingual immunotherapy during three years of treatment European Annals of Allergy and Clinical Immunology 48(6): 224-227
Bourlon, M.ía.T.; Velázquez, H.E.; Luna-Santiago, R.; Vázquez-Manjarrez, S.; Bourlon, C. 2018: Is this Patient with Metastatic Bladder Cancer a Candidate for Second-Line Immunotherapy Treatment? Oncology 32(2): 64-68
Mathé, G.; Halle-Pannenko, O.; Bourut, C. 1973: Active immunotherapy in spontaneous leukemia of AkR mice Experimental Hematology 1(2): 110-114
Lotem, M.; Shiloni, E.; Ingber, A.; Peretz, T. 1997: Active specific immunotherapy of malignant melanoma Harefuah 133(3-4): 122-126
Williams, R.; Eddleston, A.L. 1979: Chronic active hepatitis: immunopathogenesis and immunotherapy Israel Journal of Medical Sciences 15(3): 261-275
Mutzner, P.A.; Stuhlmiller, G.M.; Seigler, H.F.; Stumpf, W.E.; Sar, M. 1981: Basis for a specific-active immunotherapy in malignant melanoma Schweizerische Medizinische Wochenschrift 111(36): 1322-1325
Mellstedt, H.åk.; Veelken, H. 2005: Active immunotherapy in patients with hematologic and solid neoplasms Onkologie 28(Suppl 4): 4-8
Novak, R. 1979: A modern treatment of the bladder cancer Lijecnicki Vjesnik 101(7): 393-394
Mocellin, S. 2005: Priming anticancer active specific immunotherapy with dendritic cells Current Opinion in Investigational Drugs 6(6): 576-581